Novo Nordisk, Ozempic
Novo Nordisk’s Ozempic Shortage Is Worsening. That’s Good for Eli Lilly Stock.
While Novo is struggling to keep up with demand for its obesity drugs, U.S. rival Eli Lilly sees supply restraints easing.
Novo Nordisk's Ozempic shortage expected to continue into Q4
Novo Nordisk said the shortage of lower strengths of its diabetes drug Ozempic has deteriorated, with intermittent shortages for all strengths expected into the final quarter of 2024 due to increased demand and along with capacity constraints at some of its manufacturing sites.
Ozempic Could Have a Terrible Side Effect. Is Novo Nordisk in Trouble?
However, various potential headwinds have popped up that could disrupt Ozempic's progress. One of them is competition. Novo Nordisk's longtime foe in the diabetes market, Eli Lilly, developed Mounjaro, a diabetes medicine whose sales are growing incredibly fast.
Eli Lilly Makes Strides on Weekly Insulin Shot as Novo Nordisk Stumbles
Today, patients on insulin receive injections daily, or even more often, but both companies are working to change that.
Ozempic shortages in EU will not affect all member states - Novo Nordisk
Intermittent shortages of diabetes drug Ozempic in the European Union that are expected to continue into the final quarter of 2024 because of strong demand will not affect all member states, the Danish drugmaker Novo Nordisk said.
Novo Nordisk Warns Of Weight Loss Drug Shortage
Novo Nordisk (NVO) is warning about a growing shortage of its popular weight loss drug Ozempic. The Danish pharmaceutical company has issued a statement saying that the current shortage of Ozempic, which is also used to treat diabetes,
Novo Nordisk Files Patent Claims to Fend off Generic Rivals of Wegovy
Sun Pharma of India and Mylan Pharmaceuticals of West Virginia seek FDA approval of generic versions of the popular ...
Is Novo Nordisk A/S (NVO) A Good Biotech Stock to Buy?
We recently compiled a list of the 12 Best Biotech Stocks To Invest In According To Hedge Funds. In this article, we are ...
What the Options Market Tells Us About Novo Nordisk
Out of all of the special options we uncovered, 7 are puts, for a total amount of $295,009, and 5 are calls, for a total ...
Kepler Capital Sticks to Their Hold Rating for Novo Nordisk (0QIU)
Kepler Capital analyst David Evans maintained a Hold rating on Novo Nordisk (0QIU – Research Report) on September 6 and set a price ...
STAT9d
New Wegovy analysis could boost Novo Nordisk’s bid to expand drug’s label in heart failure
Novo Nordisk’s Wegovy cut the risk of severe complications in patients with a common form of heart failure, according to a ...
The Motley Fool8d
These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now
Eli Lilly and Novo Nordisk compete in a handful of different markets. Novo Nordisk is scaling up its output and ...
Novo to Contribute Half Danish GDP Growth in 2024, Danske Says
Novo Nordisk A/S is likely to contribute about half of Denmark’s economic expansion this year, helping the nation to ...
Novo Nordisk Reduces Price of Popular Obesity Drug Amid Rising Competition
Novo Nordisk is working to resolve supply issues that are affecting the launch of its weight-loss and diabetes medications, ...